β-Amyloid (1-42), human (TFA) [107761-42-2]
Cat# HY-P1363-1mg
Size : 1mg
Brand : MedChemExpress
β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.
For research use only. We do not sell to patients.
Custom Peptide Synthesis
β-Amyloid (1-42), human TFA Chemical Structure
This product is a controlled substance and not for sale in your territory.
Based on 11 publication(s) in Google Scholar
Other Forms of β-Amyloid (1-42), human TFA:
- β-Amyloid (1-42), human In-stock
- Biotin-β-Amyloid (1-42), human TFA Get quote
- β-Amyloid-15N (1-42), human TFA Get quote
Description |
β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease[1][2][3]. |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
In Vitro |
β-Amyloid Aggregation Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs). MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
In Vivo |
β-Amyloid (1-42), human TFA can be used in animal modeling to construct Alzheimer's disease models. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
Molecular Weight |
4628.06 |
||||||||||||
Formula |
C205H312F3N55O62S |
||||||||||||
Appearance |
Solid |
||||||||||||
Color |
White to off-white |
||||||||||||
Sequence |
Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala |
||||||||||||
Sequence Shortening |
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA |
||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere. |
||||||||||||
Storage |
Sealed storage, away from moisture
*The compound is unstable in solutions, freshly prepared is recommended. |
||||||||||||
Solvent & Solubility |
In Vitro:
DMSO : 33.33 mg/mL (7.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
The co-solvents required include: DMSO,
. All of co-solvents are available by MedChemExpress (MCE).
, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
*The compound is unstable in solutions, freshly prepared is recommended.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||
Purity & Documentation | |||||||||||||
References |
|
Complete Stock Solution Preparation Table
* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO | 1 mM | 0.2161 mL | 1.0804 mL | 2.1607 mL | 5.4018 mL |
5 mM | 0.0432 mL | 0.2161 mL | 0.4321 mL | 1.0804 mL |
β-Amyloid (1-42), human TFA Related Classifications
- Peptides
- Peptide and Derivatives
- β-Amyloid and Tau Peptides
- β-Amyloid Peptides
- Neurological Disease
- Neuronal Signaling
- Amyloid-β